Each material 8-K filed by an S&P 1500 company, read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (1506 companies, A–Z).
Encompass Health said its Sea Pines Rehabilitation Hospital in Melbourne, Florida, remains closed indefinitely after torrential rains on Nov. 1-2, 2026 caused flooding and substantial damage. The company reaffirmed its full-year 2026 guidance, which it said excludes closure-related costs and insurance proceeds from non-GAAP measures, but the closure removes a 90-bed facility from its operations while the joint venture evaluates repair or replacement options.
Sea Pines is a 90-bed hospital owned by a joint venture between Encompass Health and Holmes Regional Medical Center, a subsidiary of Health First.
For the first nine months of 2026, Sea Pines had net operating revenue of approximately $44 million and contributed approximately $14 million to Adjusted EBITDA.
Full-year 2026 guidance was reaffirmed: net operating revenue of $6,450 million to $6,500 million, Adjusted EBITDA of $1,395 million to $1,415 million, and adjusted EPS of $6.23 to $6.37.
All patients were evacuated safely, and the joint venture is in discussions with its partner on the path forward for reopening.
Home BancShares said it received about $80.7 million from the borrower's sale of part of the collateral securing a $92.1 million non-performing loan relationship in its Texas market, completing the first phase of resolving the credit. The payment lowers the company's non-performing loan and asset ratios and leaves about $11.4 million in carrying amount, with a second phase expected in the fourth quarter of 2026 that could recover part of an amount charged off in 2024.
Payment of about $80.7 million received; proceeds were about 95% of the appraised value of the collateral sold
Remaining carrying amount of about $11.4 million, still classified as nonaccrual pending the second phase
Based on September 30, 2026 balances, non-performing loans to total loans fall about 48 basis points and non-performing assets to total assets fall about 34 basis points
Second phase expected to complete in the fourth quarter of 2026, but the company gives no assurance the remaining balance will be repaid as expected
Freeport-McMoRan's Board of Directors approved a $4.5 billion expansion and modernization program for its wholly owned Bagdad copper and molybdenum operation in northwest Arizona. The filing says the project would lift annual long-term copper output to over 400 million pounds, about 225 million pounds more, with initial production targeted for mid-2030. For shareholders, this is a large, multi-year capital commitment, with planned spending to be incorporated into the company's updated capital expenditure outlook and classified as discretionary.
Future incremental capital costs for a new concentrator, mining equipment and expanded infrastructure are expected to approximate $4.5 billion.
Annual long-term production would exceed 400 million pounds of copper (about 225 million pounds incremental) and over 20 million pounds of molybdenum (about 12 million pounds incremental).
Construction is expected to take about 3.5 years, with about 20% of project costs funded in 2027, 30-35% in 2028 and the balance in 2029-2030.
Project break-even economics are supported at a copper price of approximately $4.00 per pound, and the company expects a roughly 20% reduction in long-term unit net cash costs.
Cencora reorganized its operating model and will report three segments starting in fiscal 2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. The company also furnished unaudited revised segment results for fiscal 2026 and 2025 under the new structure, which show total revenue of $337.4 billion and total segment operating income of $4.8 billion for fiscal 2026, up from $321.3 billion and $4.2 billion in fiscal 2025.
Beginning in the first quarter of fiscal 2027, reporting segments are Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other
Fiscal 2026 total revenue was $337,397,299 thousand, compared with $321,332,819 thousand in fiscal 2025
Fiscal 2026 total segment operating income was $4,813,047 thousand, compared with $4,222,973 thousand in fiscal 2025
MWI Animal Health, Profarma and other PharmaLex components are in Other, a non-reportable category where the company is exploring strategic alternatives
FirstCash furnished an November 2026 investor presentation as Exhibit 99.1 to this 8-K and posted it on its website. The deck shows revenue up 18%, GAAP EPS up 25% and adjusted EPS up 19% versus the prior year, and it reiterates the pending Ramsdens acquisition and a 10% dividend increase for shareholders.
Trailing twelve-month figures as of September 30, 2026: revenue of $4.3 billion, GAAP net income of $406 million and adjusted EBITDA of $835 million
Fourth quarter dividend declared at $0.46 per share, a 10% increase over the prior quarterly dividend, annualizing to $1.84 per share
$176 million remains under the $350 million share repurchase program, with 1.6 million shares repurchased year to date at an average price of $201.04
Ramsdens acquisition has an estimated equity value of about $304 million and is targeted to close by the end of 2026, pending antitrust approval
Strategy Inc reported its weekly update for October 26 to November 1, 2026, in which it bought 811 bitcoin for $65.5 million using net proceeds from MSTR Stock sales. It also repurchased about 2.09 million STRC preferred shares for $208.2 million, funded from USD Cash. The filing shows bitcoin holdings of 849,327 BTC and a USD Reserve balance of $4.79 billion as of November 1, 2026.
Bought 811 bitcoin for $65.5 million at an average price of $80,846; aggregate holdings reached 849,327 BTC
Sold 1,178,552 MSTR Stock shares for $164.0 million in net proceeds; $98.5 million allocated to USD Cash
Repurchased 2,092,035 STRC preferred shares for $208.2 million; $748.6 million remains under the preferred repurchase program
USD Reserve stood at $4.79 billion and USD Cash at $132.7 million as of November 1, 2026
Cullen/Frost Bankers said it will voluntarily move the listings of its common stock and Series B preferred depositary shares from the New York Stock Exchange to the Texas Stock Exchange. Trading on the TXSE is expected to begin November 12, 2026, and the tickers CFR and CFR.PrB will stay the same, with the company stating no shareholder action is required.
NYSE trading in common stock (CFR) and depositary shares (CFR.PrB) is expected to end at market close on November 11, 2026.
TXSE trading is expected to begin at market open on November 12, 2026, under the existing symbols.
The filing states no action is required from Cullen/Frost shareholders for the transfer.
The company reported $54.5 billion in assets at September 30, 2026.
Centrus Energy said its Oak Ridge, Tennessee plant has completed and shipped the first new centrifuge for its multibillion-dollar uranium enrichment expansion, with components to be assembled in Ohio. The company said this and a complete domestic supply chain were achieved ahead of its previously announced year-end target, but the filing contains no financial results or updated guidance.
First new centrifuge completed and shipped from Oak Ridge on October 29, 2026, ahead of the previously announced year-end target.
Centrus said it completed its acquisition of Westerman Holdings, a supplier of centrifuge casings, earlier in October 2026.
The company announced a $560 million investment in January 2026 to expand its Oak Ridge plant, and first new capacity in Ohio is expected to come online in 2029.
Xencor said its current operating plans give it cash to fund research, development and operations into 2029. The company also released updated Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, reporting confirmed objective response rates of 30.0% to 45.5% across three dose levels. The data are early and come from small groups, and the filing reports high rates of grade 3 or higher adverse events.
Cash expected to fund R&D and operations into 2029, based on current operating plans.
Confirmed objective response rate: 30.0% at 100 μg/kg (n=30), 44.0% at 200 μg/kg (n=25), 45.5% at 400 μg/kg (n=11).
Grade 3 or higher treatment-emergent adverse events occurred in 82.4% of expansion-dose patients (n=68); one treatment discontinuation due to cytokine release syndrome was reported.
Full 400 μg/kg analysis expected during 1H 2027 (20+ patients); a potential registration-enabling study is planned to start in 2027.
Black Hills Corp. announced the planned name and ticker for the combined company if its merger with NorthWestern Energy receives final Montana regulatory approval and closes. Shareholders need take no action, and BKH shares continue trading under their current symbol while the merger is pending.
Black Hills would be renamed Bright Horizon Energy Corporation and trade on the NYSE as HZN after the merger completes.
NorthWestern Energy would become a wholly owned subsidiary of Bright Horizon Energy.
The Montana Public Service Commission is expected to consider the merger before November 12, 2026.
Shareholders of both companies, the Nebraska and South Dakota commissions, FERC and Hart-Scott-Rodino clearance have already approved or cleared the merger.
Bread Financial reported September 2026 credit metrics, including a delinquency rate of 5.57%, down from 6.04% a year earlier. Average credit card and other loans rose 6.4% year over year for the month, to $18.74 billion. The release does not include revenue, earnings or guidance, and the filing gives no prior-year comparison for net principal loss rates.
Delinquency rate was 5.57% as of September 30, 2026, versus 6.04% as of September 30, 2025.
Net principal loss rate was 5.99% for September 2026 and 6.40% for the three months ended September 30, 2026.
Average credit card and other loans rose 6.4% year over year for September to $18.74 billion; end-of-period loans were $18.85 billion.
At its 2026 Investor Meeting on October 19, 2026, Jefferies presented trailing 12-month results that management described as strong, including net revenues of $8.5 billion, net earnings above $935 million, and a return on tangible equity of 13.1%. Management said it expects investment banking and capital markets margins to keep expanding and that it expects to close the Hildene transaction in the first quarter of 2027.
Trailing 12-month net revenues of $8.5 billion, net earnings over $935 million, and return on tangible equity of 13.1%
Investment banking and capital markets segment revenue rose from $4.5 billion in 2023 to $7.8 billion, and pre-tax profit rose from $500 million to about $1.3 billion
Over $925 million returned to shareholders in the current year through buybacks and dividends
Management expects to close the Hildene transaction in the first quarter of 2027
Arcus Biosciences presented new data from its ARC-20 platform study of casdatifan, alone or in combination, for clear cell renal cell carcinoma, using a data cutoff of September 4, 2026. The filing reports response, progression and survival figures across first-line, second-line and late-line cohorts, with no unexpected safety signals cited for each regimen.
Second-line casdatifan plus cabozantinib (n=43): median PFS 14.5 months, 18-month landmark overall survival 77%, cORR 44%
First-line casdatifan plus zimberelimab (n=30): cORR 50%, landmark PFS 69% at 12 months, primary progression 6.7%
Late-line casdatifan monotherapy (n=121): median overall survival 35 months, median PFS 13 months, cORR 36%
Hilton notified the New York Stock Exchange that it will voluntarily transfer the listing of its common stock to the Nasdaq Global Select Market. The stock will keep the ticker HLT, and no action is required from shareholders. The filing reports no change to financial results or business strategy, so the move mainly affects where shares are listed and traded.
NYSE trading in Hilton common stock is expected to end at market close on November 4, 2026.
Trading on Nasdaq is expected to begin at market open on November 5, 2026, under the existing ticker HLT.
The press release says the transfer does not alter Hilton's business strategy or capital allocation priorities.
Hilton's CEO Chris Nassetta said the company is grateful to the NYSE for its longstanding partnership.
Jefferies Financial Group posted an investor presentation on its website for its October 19, 2026 investor meeting, furnished as Exhibit 99.1 to a Form 8-K. The deck reports trailing-twelve-month results through the third quarter of 2026, including $8.5 billion in net revenues and $0.9 billion in net earnings to all shareholders, and it reviews its pending acquisition of Hildene/SILAC and a planned Japan Equities joint venture with SMBC.
Presentation posted October 19, 2026 for the company's October 19, 2026 Investor Meeting; filed as Exhibit 99.1
LTM Q3'26 net revenues of $8.5 billion, up 119% since 2019; net earnings to all shareholders of $0.9 billion, up 123% since 2019
Pending acquisition: Jefferies intends to acquire a 50% interest in Hildene Holding Company, which is acquiring SILAC, as disclosed in September 2025
Japan Equities joint venture with SMBC is scheduled to launch January 1, 2027
Emerson Electric said it changed its method of accounting for pension and other postretirement benefit plans to mark-to-market, effective for fiscal 2026, and filed recast historical results. The change adds $8 million to pretax earnings for the nine months ended June 30, 2026, and the company expects a pretax mark-to-market gain of less than $5 million in the fourth quarter of fiscal 2026, which was not in its previous outlook. The change has no effect on cash flows, plan funding or benefits payable.
Nine-month pretax earnings rise $8 million; after-tax $6 million, or $0.01 per share
Fourth-quarter fiscal 2026 mark-to-market gain expected to be less than $5 million pretax
Adjusted earnings per share will exclude the annual mark-to-market adjustment
Change applied retrospectively; recast results are in Exhibit 99.1 and are not a restatement
Tesla reported preliminary third-quarter 2026 production, delivery and energy storage deployment figures in a press release furnished as Exhibit 99.1 to a Form 8-K dated October 2, 2026. The release does not include net income or cash flow, which Tesla says will be announced with its Q3 2026 earnings on October 21, 2026, and the company notes these operating figures are not an indicator of quarterly financial results.
Vehicle deliveries totaled 486,532 in Q3 2026, including 478,237 Model 3/Y and 8,295 other models.
Vehicle production totaled 464,391 in Q3 2026, including 457,387 Model 3/Y and 7,004 other models.
Energy storage deployments totaled 13.7 GWh in the third quarter of 2026.
Tesla will report Q3 2026 financial results after market close on Wednesday, October 21, 2026, with a webcast at 5:30 p.m. Eastern Time.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by S&P 500, MidCap 400 and SmallCap 600 companies that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
The SEC filing feed is checked every hour on weekdays between 7 am and 9 pm Eastern; briefs follow within that hour or, when many filings arrive at once, later the same day.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.